您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > Oleyloxyethyl Phosphorylcholine
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Oleyloxyethyl Phosphorylcholine
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Oleyloxyethyl Phosphorylcholine图片
CAS NO:84601-19-4
包装与价格:
包装价格(元)
10mg (solution)电议
50mg (solution)电议

产品介绍

化学性质

Physical AppearanceA solution in ethanol. To change the solvent, simply evaporate the ethanol under a gentle stream of nitrogen and immediately add the solvent of choice.
StorageStore at -20°C
M.Wt477.7
Cas No.84601-19-4
FormulaC25H52NO5P
Solubility≤16mg/ml in DMSO;16mg/ml in dimethyl formamide
Chemical Name1-O-9Z-octadecenylethyleneglycol-2-O-phosphorylcholine
Canonical SMILESCCCCCCCC/C=C\CCCCCCCCOCCOP([O-])(OCC[N+](C)(C)C)=O
运输条件蓝冰运输或根据您的需求运输。
一般建议为了使其更好的溶解,请用37℃加热试管并在超声波水浴中震动片刻。不同厂家不同批次产品溶解度各有差异,仅做参考。若实验所需浓度过大至产品溶解极限,请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存,请尽快用完。

资料参考

IC50: 6.2 μM for porcine pancreatic PLA2

Oleyloxyethyl phosphorylcholine is a PLA2 inhibitor.

Phospholipases A2 (PLA2s) are enzymes releasing fatty acids from glycerol. This particular phospholipase can specifically recognize the sn-2 acyl bond of phospholipids and catalytically hydrolyze the bond releasing arachidonic acid and lysophosphatidic acid. Upon downstream modification by cyclooxygenases, arachidonic acid is modified into active eicosanoids, which are categorized as anti-inflammatory and inflammatory mediators.

In vitro: To examine the phospholipids including oleyloxyethyl phosphorylcholine as PLA2 inhibitors, the enzyme assay was employed. Determinations were performed below critical micelle concentration. Porcine pancreatic PLA2 and phospholipid inhibitor were preincubated for 2 min at 37°C in buffer at pH 8.5. Introduction of [l4C]arachidonate phosphatidylcholine initiated the enzymatic reaction, which is quenched after 5 min at 37°C. In this manner 50% inhibitor concentrations were determined for mepacrine and alkylphosphorylcholines, indicating oleyloxyethyl phosphorylcholine was an inhibitor of PLA2 with an IC50 of 6.2 μM for porcine pancreatic PLA2 [1].

In vivo: Up to now, there is no animal in vivo data reported.

Clinical trial: So far, no clinical study has been conducted.

Reference:
[1] Magolda, R. L.,Ripka, W.C.,Galbraith, W., et al. Novel synthesis of potent site-specific phospholipase A2 inhibitors. Book: Prostaglandins, Leukotrienes and Lipoxins 669-676 (1985).